Article Text

Download PDFPDF
CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies
  1. Brit Mollenhauer1,
  2. Michael G Schlossmacher2
  1. 1Paracelsus-Elena-Klinik, Kassel and Georg-August-University Goettingen, Germany
  2. 2Division of Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada
  1. Correspondence to Dr Brit Mollenhauer, Paracelsus-Elena-Klinik, Klinikstrasse 16, D-34128 Kassel, Germany; brit.mollenhauer{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia disorder. Lack of awareness, frequent misdiagnosis and its poorly understood pathogenesis represent key impediments to improved care. A related challenge is the overlap between DLB and Alzheimer's disease (AD). Applying currently available clinical guidelines, DLB is a well-defined dementia with high specificity but low sensitivity,1 thereby highlighting the need for validated biomarkers.

The quantification of neural proteins in cerebrospinal fluid (CSF) for biomarker purposes has received enormous impetus from the AD field. AD is characterised by β-amyloidosis and tauopathy. In accordance, measurements of CSF β-amyloid and τ have become important in the early and differential diagnoses of dementia. …

View Full Text


  • Linked articles 197483.

  • Competing interests BM and MGS are listed as coinventors of a patent application to the US Patent Office relating to a method to diagnose neurodegenerative diseases.

  • Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles